Understanding risks associated with primary biliary cirrhosis (PBC) recurrence after liver transplantation may affect immunosuppression.
In this study, researchers from England evaluated 485 patients with primary biliary cirrhosis.
Patients were followed for a median of 79 months after transplantation.
The team found histological evidence of recurrence was found in 23%.
|The odds ratio for recurrence on tacrolimus was 2.73, compared with cyclosporine.|
On multivariate analysis, the only risk factor identified with recurrence was the type of calcineurin inhibitor used.
The researchers determined that the odds ratio for recurrence on tacrolimus was 2.73 compared with cyclosporine.
For patients receiving cyclosporine, median time to recurrence was 123 months and for those on tacrolimus 62 months.
Dr James Neuberger's team concluded, "Reasons for this difference between the 2 calcineurin inhibitors are not clear".